| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8535732 | Life Sciences | 2018 | 21 Pages |
Abstract
The combination of naringin and pravastatin did not appear to be better than monotherapy on lipids, but its use could generate euglycemic and antiobesogenic effects, in addition to diminishing the adverse hepatic effects of pravastatin in rats.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Abdel K. Raffoul-Orozco, Ana E. Ávila-González, Christian M. RodrÃguez-Razón, Teresa A. GarcÃa-Cobian, Edsaul E. Pérez-Guerrero, Trinidad GarcÃa-Iglesias, Edy David Rubio-Arellano,